Structure Therapeutics Inc.
GPCRNASDAQHealthcare● Active
$36.90
$-0.68(-1.81%)
Market Cap$2.1B
P/E Ratio—
52W High$94.9
52W Low$15.8
Structure Therapeutics Inc. (GPCR) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
GPCR · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$0.35
Est. -$0.39 · +10.3%
Revenue
—
Est. $0.01B
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
GPCR reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.37
Rev. $0.36B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.37
Rev. Est.$0.36B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$0.39 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 7, 2026 | -$0.39 | -$0.35 | +10.3% | — | $0.01B | — |
| ▼ Q1 FY2026 | Feb 26, 2026 | -$0.35 | -$0.49 | -40.0% | — | $0.01B | — |
| ▼ Q4 FY2025 | Nov 6, 2025 | -$0.36 | -$0.37 | -2.8% | — | — | — |
| ▼ Q3 FY2025 | Aug 6, 2025 | -$0.28 | -$0.36 | -28.6% | — | — | — |
| ▼ Q2 FY2025 | May 8, 2025 | -$0.24 | -$0.27 | -12.5% | — | — | — |
| ▲ Q1 FY2025 | Feb 27, 2025 | -$0.23 | -$0.22 | +4.3% | $0.00B | — | — |
| ▼ Q4 FY2024 | Nov 13, 2024 | -$0.19 | -$0.20 | -5.3% | — | — | — |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$0.39
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Beat
EPS Actual
-$0.35
EPS Est.
-$0.39
EPS Surpr.
+10.3%
Revenue
—
Q1 FY2026
Feb 26, 2026Miss
EPS Actual
-$0.49
EPS Est.
-$0.35
EPS Surpr.
-40.0%
Revenue
—
Q4 FY2025
Nov 6, 2025Miss
EPS Actual
-$0.37
EPS Est.
-$0.36
EPS Surpr.
-2.8%
Revenue
—
Q3 FY2025
Aug 6, 2025Miss
EPS Actual
-$0.36
EPS Est.
-$0.28
EPS Surpr.
-28.6%
Revenue
—
Q2 FY2025
May 8, 2025Miss
EPS Actual
-$0.27
EPS Est.
-$0.24
EPS Surpr.
-12.5%
Revenue
—
Q1 FY2025
Feb 27, 2025Beat
EPS Actual
-$0.22
EPS Est.
-$0.23
EPS Surpr.
+4.3%
Revenue
$0.00B
Q4 FY2024
Nov 13, 2024Miss
EPS Actual
-$0.20
EPS Est.
-$0.19
EPS Surpr.
-5.3%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-0.59 | $-0.59 | $-0.59 | 5 |
| Q3 FY2028 | $-0.59 | $-0.59 | $-0.59 | 5 |
| Q2 FY2028 | $-0.60 | $-0.60 | $-0.60 | 6 |
| Q1 FY2028 | $-0.60 | $-0.60 | $-0.60 | 3 |
| Q4 FY2027 | $-0.75 | $-0.75 | $-0.75 | 2 |
| Q3 FY2027 | $-0.51 | $-0.51 | $-0.51 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +10.3% | $40.84 | $39.15 | -4.14% |
| ▼ Q1 FY2026 | Feb 26, 2026 | -40.0% | $66.53 | $64.75 | -2.68% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -2.8% | $32.21 | $33.47 | +3.91% |
| ▼ Q3 FY2025 | Aug 6, 2025 | -28.6% | $16.68 | $16.31 | -2.22% |
| ▼ Q2 FY2025 | May 8, 2025 | -12.5% | $26.60 | $26.82 | +0.83% |
| ▲ Q1 FY2025 | Feb 27, 2025 | +4.3% | $19.88 | $22.82 | +14.79% |
| ▼ Q4 FY2024 | Nov 13, 2024 | -5.3% | $36.97 | $36.37 | -1.62% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +21.7% | $34.03 | $34.49 | +1.35% |
Q2 FY2026-4.14%
Report Date
May 7, 2026
EPS Beat/Miss
+10.3%
Price Before
$40.84
Price After
$39.15
Q1 FY2026-2.68%
Report Date
Feb 26, 2026
EPS Beat/Miss
-40.0%
Price Before
$66.53
Price After
$64.75
Q4 FY2025+3.91%
Report Date
Nov 6, 2025
EPS Beat/Miss
-2.8%
Price Before
$32.21
Price After
$33.47
Q3 FY2025-2.22%
Report Date
Aug 6, 2025
EPS Beat/Miss
-28.6%
Price Before
$16.68
Price After
$16.31
Q2 FY2025+0.83%
Report Date
May 8, 2025
EPS Beat/Miss
-12.5%
Price Before
$26.60
Price After
$26.82
Q1 FY2025+14.79%
Report Date
Feb 27, 2025
EPS Beat/Miss
+4.3%
Price Before
$19.88
Price After
$22.82
Q4 FY2024-1.62%
Report Date
Nov 13, 2024
EPS Beat/Miss
-5.3%
Price Before
$36.97
Price After
$36.37
Q3 FY2024+1.35%
Report Date
Aug 8, 2024
EPS Beat/Miss
+21.7%
Price Before
$34.03
Price After
$34.49
Avg Beat Reaction+4.00%
Avg Miss Reaction-0.36%
Beat Rate3 / 8 quarters
Largest Move+14.79% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: GPCR ends December
Structure Therapeutics Inc. (GPCR) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-0.35 — beating the analyst consensus of $-0.39 by +10.3%. The next GPCR earnings date is expected around September 1, 2026.
Each quarter, investors track GPCR earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. GPCR revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
GPCR's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
GPCR earnings · 5 questionsStructure Therapeutics Inc.'s next earnings report is expected around September 1, 2026. GPCR typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; GPCR historically reports after market close (AMC).
GPCR earnings datewhen is GPCR earningsGPCR next earnings datewhen does GPCR report earningsGPCR earnings calendar
▸ Source: FMP · Structure Therapeutics Inc. SEC filings · US GAAP · Structure Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026